IBUPROFEN | A075682 | DR REDDYS LABORATORIES INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Hyman, Phelps & McNamara, P.C. FDA-2026-P-3631 · 7 docket documents Hyman, Phelps & McNamara, P.C. filed this suitability petition on behalf of a client requesting that the FDA declare Ibuprofen Tablets, 1,200 mg, suitable for submission as an ANDA under Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act, with the RLD being MOTRIN (ibuprofen) Tablets a | Suitability | 2026-04-02 | Open | Hyman, Phelps & McNamara, P.C. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.0561
per ea
Lowest NADAC/Unit
$0.0397
per ea
Brand NDCs
0
Generic NDCs
15
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 55111068401IBU 800 MG TABLET | $0.0561 | EA | Generic | — | 2026-06-17 |
| 55111068405IBU 800 MG TABLET | $0.0561 | EA | Generic | — | 2026-06-17 |
| 00904585540IBUPROFEN 800 MG TABLET | $0.0561 | EA | Generic | — | 2026-06-17 |
| 00904585560IBUPROFEN 800 MG TABLET | $0.0561 | EA | Generic | — | 2026-06-17 |
| 00904585561IBUPROFEN 800 MG TABLET | $0.0561 | EA | Generic | — | 2026-06-17 |
| 00904585461IBUPROFEN 600 MG TABLET | $0.0443 | EA | Generic | — | 2026-06-17 |
Showing 6 of 15 NDCs.
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.